Business
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors Company
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\n Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors\n\n\nCompany reminds shareholders to vote today to protect the value of their investment and ensure Aurinia’s continued momentum\n\n\nShareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at [email protected].\n\n\n EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that Glass Lewis & Co. (“Glass Lewis”), a leading independent proxy advisor, has recommended that Aurinia shareholders vote FOR ALL proposals at the Company’s 2023 Annual General Meeting (the “Meeting”), including the re-election to the Board of Directors (the “Board”) of all eight incumbent directors and the approval of the Company’s say-on-pay resolution.\n\n\nGlass Lewis is an independent proxy advisor to institutional investors, covering 30,000 shareholder meetings each year, across approximately 100 global markets. Their customers include the majority of the world’s largest pension plans, mutual funds, and asset managers who collectively manage over $40 trillion in assets.\n\n\nThe Board encourages all shareholders eligible to vote at the Meeting to do so today using the instructions provided below.\n\n\nThe virtual-only meeting will be held via live audio webcast online using the LUMI meeting platform at https://web.lumiagm.com/467056294 (password (case sensitive): aurinia2023) on Wednesday, May 17, 2023 at 12:00 pm, Eastern Time.\n\n\nAurinia has the right Board and management team to drive continued momentum and enhance shareholder value.\n\n\nOur Board and management team have the right skills and expertise to continue to unlock value for all shareholders. Each director brings deep expertise in areas critical to the growth of our business, including the commercialization of pharmaceutical and biotech products, business development, and international pharmaceutical operations. Additionally, five of our eight directors bring R&D experience, six have clinical development expertise, and four have served in c-suite roles.\n\n\nAurinia’s Board and management team remain focuse...